152 related articles for article (PubMed ID: 7577342)
21. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
22. Cytokines in anticancer therapy.
Khan IU; Shear NH
Clin Dermatol; 1991; 9(4):523-33. PubMed ID: 1726586
[No Abstract] [Full Text] [Related]
23. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
24. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
Yaron I; Zakheim AR; Oluwole SF; Hardy MA
Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
[No Abstract] [Full Text] [Related]
25. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
Clark J; Longo DL
Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
[No Abstract] [Full Text] [Related]
26. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A
Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
29. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
30. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.
Agah R; Malloy B; Kerner M; Mazumder A
J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
32. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy for cancer.
Rosenberg SA
Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
[No Abstract] [Full Text] [Related]
34. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
[TBL] [Abstract][Full Text] [Related]
35. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
[TBL] [Abstract][Full Text] [Related]
36. Easing the side effects of IL-2-LAK cell therapy.
Oncology (Williston Park); 1988 May; 2(5):61, 64. PubMed ID: 3275159
[No Abstract] [Full Text] [Related]
37. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
38. T-cell growth factors and the treatment of patients with cancer.
Lotze MT
Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S47-54. PubMed ID: 1728987
[TBL] [Abstract][Full Text] [Related]
39. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
[TBL] [Abstract][Full Text] [Related]
40. Recombinant antibody fusion proteins for cancer immunotherapy.
Reisfeld RA; Gillies SD
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
